**Supplementary table 1: Patients’ clinical characteristics in GSE73517 dataset**

|  |  |  |
| --- | --- | --- |
| **Characteristics** |  | **Patients number** |
| Age (year) | >=1.5 | 43 |
| <1.5 | 62 |
| INSS stage | 1 | 10 |
| 2 | 9 |
| 3 | 10 |
| 4 | 56 |
| 4S | 20 |
| Risk category | Low | 40 |
| Intermediate | 9 |
| High | 56 |
| MYCN status | Amplified | 33 |
| Non-amplified | 72 |
| 1p status | Deletion | 44 |
| Gain | 4 |
| Normal | 57 |
| 11q status | Deletion | 29 |
| Gain | 1 |
| Whole loss | 23 |
| Normal | 52 |
| 17q status | Gain | 92 |
| Normal | 13 |

**Supplementary table 1: Patients’ clinical characteristics in GSE120572 dataset**

|  |  |  |
| --- | --- | --- |
| **Characteristics** |  | **Patients number** |
| Age (year) | >=1.5 | 199 |
| <1.5 | 195 |
| INSS stage | 1 | 55 |
| 2 | 67 |
| 3 | 58 |
| 4 | 168 |
| 4S | 46 |
| MYCN status | Amplified | 83 |
| Non-amplified | 310 |
| N/A | 1 |

**Supplementary table 1: MYCN status in stage 4 and stage 4S**

|  |  |  |
| --- | --- | --- |
|  |  | **Patients number** |
| **INSS Satge** | **Status** | **GSE73517** | **GSE120572** |
| Stage 4 | Amplified | 26 | 58 |
| Non-amplified | 30 | 109 |
| Stage 4S | Amplified | 3 | 6 |
| Non-amplified | 17 | 40 |